Learning to program in C on an online platform can provide structured learning and a certification to show along with your resume. Learning C can still be useful in 2026, especially if you want to ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Health Canada ‌ ...

April 28 (Reuters) - Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes drug Ozempic made by Indian drugmaker Dr ...

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...

Generic dapagliflozin is indicated for adults with type 2 diabetes and to reduce heart failure hospitalization risk in adults with T2D and established cardiovascular disease. The Food and Drug ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Merck’s guidance for the year—anticipating sales between 20 billion euros and 21 billion euros, or -1% to 2% growth— “assumes no U.S. sales of Mavenclad from March 2026 amid generic competition.” ...